14 results on '"Liz Flavell"'
Search Results
2. Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1
- Author
-
Liz Flavell, Jakub Luptak, David J. Hargreaves, Steven L. Kazmirski, Tina Howard, Kate F. Wickson, Ning Gao, David I Fisher, Michal Bista, and Philip B. Rawlins
- Subjects
Programmed cell death ,Myeloid ,drug design ,Cell ,Apoptosis ,CHO Cells ,scFv ,03 medical and health sciences ,Immunoglobulin Fab Fragments ,0302 clinical medicine ,Cricetulus ,Structural Biology ,hemic and lymphatic diseases ,Drug Discovery ,medicine ,Escherichia coli ,Animals ,Humans ,Fab ,Cloning, Molecular ,030304 developmental biology ,0303 health sciences ,biology ,Drug discovery ,Chemistry ,Cancer ,Mcl-1 ,medicine.disease ,Research Papers ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Myeloid Cell Leukemia Sequence 1 Protein ,Antibody ,Function (biology) ,Single-Chain Antibodies - Abstract
Mcl-1 is an important cancer target for drug therapy, through which normal apoptosis may be restored by inhibiting its protective function. An scFv and a Fab have been used to generate an apo Mcl-1 crystal system that is amenable to iterative structure-guided drug design., Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) family, including Mcl-1 (myeloid cell leukaemia 1). This makes Mcl-1 a potential target for drug therapy, through which normal apoptosis may be restored by inhibiting the protective function of Mcl-1. Here, the discovery and biophysical properties of an anti-Mcl-1 antibody fragment are described and the utility of both the scFv and Fab are demonstrated in generating an Mcl-1 crystal system amenable to iterative structure-guided drug design.
- Published
- 2019
3. Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors
- Author
-
David Hargeaves, Elizabeth England, Robert M. Woods, Michael Fung, Caroline Colley, Paul Warrener, Liz Flavell, Sudharsan Sridharan, Judit E. Debreczeni, Jessica Bonnell, Claire Dobson, Jingying Zha, Bryan M. Edwards, Ling-Ling An, Laura Eghobamien, Ulf Sivars, Joanne Arnold, Jonathan Renshaw, Bojana Popovic, Kate F. Wickson, Tristan J. Vaughan, and Trevor Wilkinson
- Subjects
0301 basic medicine ,antibody co–crystal structure ,complement C5a receptor ,medicine.drug_class ,Protein Conformation ,Immunology ,Antibody Affinity ,chemical and pharmacologic phenomena ,Complement C5a ,Immune receptor ,Monoclonal antibody ,Protein Engineering ,Epitope ,03 medical and health sciences ,Epitopes ,Structure-Activity Relationship ,0302 clinical medicine ,Antibody Specificity ,Report ,C5a neutralization ,medicine ,Immunology and Allergy ,Humans ,Anaphylatoxin ,Receptor ,Receptor, Anaphylatoxin C5a ,C5a epitope ,Linear epitope ,biology ,C5a crystal structure ,Chemistry ,Antibodies, Monoclonal ,hemic and immune systems ,respiratory system ,Molecular biology ,Cell biology ,C5aR2 ,030104 developmental biology ,Epitope mapping ,C5aR1 ,HEK293 Cells ,030220 oncology & carcinogenesis ,biology.protein ,Receptors, Chemokine ,human monoclonal antibody ,Binding Sites, Antibody ,Antibody ,Epitope Mapping ,Protein Binding - Abstract
C5a is a potent anaphylatoxin that modulates inflammation through the C5aR1 and C5aR2 receptors. The molecular interactions between C5a–C5aR1 receptor are well defined, whereas C5a–C5aR2 receptor interactions are poorly understood. Here, we describe the generation of a human antibody, MEDI7814, that neutralizes C5a and C5adesArg binding to the C5aR1 and C5aR2 receptors, without affecting complement–mediated bacterial cell killing. Unlike other anti–C5a mAbs described, this antibody has been shown to inhibit the effects of C5a by blocking C5a binding to both C5aR1 and C5aR2 receptors. The crystal structure of the antibody in complex with human C5a reveals a discontinuous epitope of 22 amino acids. This is the first time the epitope for an antibody that blocks C5aR1 and C5aR2 receptors has been described, and this work provides a basis for molecular studies aimed at further understanding the C5a–C5aR2 receptor interaction. MEDI7814 has therapeutic potential for the treatment of acute inflammatory conditions in which both C5a receptors may mediate inflammation, such as sepsis or renal ischemia–reperfusion injury.
- Published
- 2017
4. Potent and selective bivalent inhibitors of BET bromodomains
- Author
-
Dmitri I. Svergun, Huawei Chen, Romel Bobby, Natalie Stratton, Danette L. Daniels, Scott Boiko, Rowena Callis, Yi Yao, Graeme R. Robb, Alfred A. Rabow, Mark S. B. McAlister, Graeme Walker, Joe Patel, Matthew B. Robers, Derek Ogg, Sakina Saif, Liz Flavell, Philip Petteruti, Austin Dulak, Ian L. Dale, Jacqui Méndez, Thomas A. Jowitt, Michael J. Waring, David Matthew Wilson, David Whittaker, Wenxian Wang, Edwin Clark, Alexey Kikhney, Geoff Holdgate, and Rob H. Bradbury
- Subjects
0301 basic medicine ,BRD4 ,Chemistry ,Stereochemistry ,Ligand ,Protein subunit ,Cell Biology ,Bivalent (genetics) ,Bromodomain ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Biochemistry ,030220 oncology & carcinogenesis ,Molecular Biology - Abstract
Proteins of the bromodomain and extraterminal (BET) family, in particular bromodomain-containing protein 4 (BRD4), are of great interest as biological targets. BET proteins contain two separate bromodomains, and existing inhibitors bind to them monovalently. Here we describe the discovery and characterization of probe compound biBET, capable of engaging both bromodomains simultaneously in a bivalent, in cis binding mode. The evidence provided here was obtained in a variety of biophysical and cellular experiments. The bivalent binding results in very high cellular potency for BRD4 binding and pharmacological responses such as disruption of BRD4-mediator complex subunit 1 foci with an EC50 of 100 pM. These compounds will be of considerable utility as BET/BRD4 chemical probes. This work illustrates a novel concept in ligand design-simultaneous targeting of two separate domains with a drug-like small molecule-providing precedent for a potentially more effective paradigm for developing ligands for other multi-domain proteins.
- Published
- 2016
- Full Text
- View/download PDF
5. Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence
- Author
-
Kevin J. Embrey, Alexander L. Breeze, Uybach Vo, Liz Flavell, Romel Bobby, Navratna Vajpai, and Alexander P. Golovanov
- Subjects
0301 basic medicine ,Son of Sevenless Protein, Drosophila ,Magnetic Resonance Spectroscopy ,GTP' ,nuclear magnetic resonance (NMR) ,genetic processes ,Allosteric regulation ,Son of Sevenless ,Guanosine Diphosphate ,Biochemistry ,Fluorescence ,Proto-Oncogene Proteins p21(ras) ,protein-protein interaction ,Nucleotide exchange factor ,03 medical and health sciences ,chemistry.chemical_compound ,Catalytic Domain ,Humans ,Small GTPase ,Sos protein ,Molecular Biology ,biology ,Chemistry ,Cell Biology ,biochemical phenomena, metabolism, and nutrition ,allosteric regulation ,enzymes and coenzymes (carbohydrates) ,030104 developmental biology ,small GTPase ,Guanosine diphosphate ,biology.protein ,Biophysics ,bacteria ,Guanosine Triphosphate ,Guanine nucleotide exchange factor ,Ras protein ,Allosteric Site ,Protein Binding - Abstract
The activity of Ras is controlled by the interconversion between GTP- and GDP-bound forms partly regulated by the binding of the guanine nucleotide exchange factor Son of Sevenless (Sos). The details of Sos binding, leading to nucleotide exchange and subsequent dissociation of the complex, are not completely understood. Here, we used uniformly (15)N-labeled Ras as well as [(13)C]methyl-Met,Ile-labeled Sos for observing site-specific details of Ras-Sos interactions in solution. Binding of various forms of Ras (loaded with GDP and mimics of GTP or nucleotide-free) at the allosteric and catalytic sites of Sos was comprehensively characterized by monitoring signal perturbations in the NMR spectra. The overall affinity of binding between these protein variants as well as their selected functional mutants was also investigated using intrinsic fluorescence. The data support a positive feedback activation of Sos by Ras·GTP with Ras·GTP binding as a substrate for the catalytic site of activated Sos more weakly than Ras·GDP, suggesting that Sos should actively promote unidirectional GDP → GTP exchange on Ras in preference of passive homonucleotide exchange. Ras·GDP weakly binds to the catalytic but not to the allosteric site of Sos. This confirms that Ras·GDP cannot properly activate Sos at the allosteric site. The novel site-specific assay described may be useful for design of drugs aimed at perturbing Ras-Sos interactions.
- Published
- 2016
- Full Text
- View/download PDF
6. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation
- Author
-
Dorothy A. Sims, Richard D. May, Tomas Mustelin, Joanne Woods, David C. Lowe, Denice T. Y. Chan, Laura Rapley, Benjamin Kemp, Matthew A. Sleeman, Nicholas J. Bond, Christel Séguy Veyssier, Liz Flavell, Katherine A. Vousden, Tristan J. Vaughan, Sara Carmen, Kevin J. Embrey, Overed-Sayer Catherine L, Catherine E. Huntington, Christopher E. Brightling, Michael R. Snaith, Bojana Popovic, D. Gareth Rees, Strain Martin D, Ian C. Scott, E. Suzanne Cohen, Jianqing Xu, Dominic J. Corkill, Jayesh B. Majithiya, Daniel R. Higazi, Elizabeth England, and Robin Butler
- Subjects
Male ,Interleukin-1 Receptor-Like 1 Protein ,General Physics and Astronomy ,Receptors, Cell Surface ,Inflammation ,Biology ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mice ,Extracellular ,medicine ,Animals ,Humans ,Receptor ,Mice, Inbred BALB C ,Multidisciplinary ,Interleukin ,Biological activity ,Receptors, Interleukin ,General Chemistry ,Interleukin-33 ,Asthma ,Cell biology ,Interleukin 33 ,Respiratory epithelium ,medicine.symptom ,Oxidation-Reduction - Abstract
In response to infections and irritants, the respiratory epithelium releases the alarmin interleukin (IL)-33 to elicit a rapid immune response. However, little is known about the regulation of IL-33 following its release. Here we report that the biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by the formation of two disulphide bridges, resulting in an extensive conformational change that disrupts the ST2 binding site. Both reduced (active) and disulphide bonded (inactive) forms of IL-33 can be detected in lung lavage samples from mice challenged with Alternaria extract and in sputum from patients with moderate–severe asthma. We propose that this mechanism for the rapid inactivation of secreted IL-33 constitutes a ‘molecular clock' that limits the range and duration of ST2-dependent immunological responses to airway stimuli. Other IL-1 family members are also susceptible to cysteine oxidation changes that could regulate their activity and systemic exposure through a similar mechanism., IL-33, released by epithelial cells in response to stress, is a potent activator of inflammation. Here Cohen et al. show that secreted IL-33 is rapidly inactivated by disulfide bond formation that prevents binding to its receptor, and that IL-33-related cytokines are susceptible to similar oxidation.
- Published
- 2015
- Full Text
- View/download PDF
7. Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease
- Author
-
Leen J M Seys, Bart N. Lambrecht, Ken R. Bracke, Ronald Herbst, Eileen McCall, Claudie Bantsimba-Malanda, Sharen Provoost, Danen Cunoosamy, Anja Schinwald, Guy Brusselle, Hamida Hammad, Guy Joos, Alan Sabirsh, Fien M. Verhamme, and Liz Flavell
- Subjects
Pulmonary and Respiratory Medicine ,Male ,Lymphoid Tissue ,Inflammation ,Enzyme-Linked Immunosorbent Assay ,Adaptive Immunity ,Critical Care and Intensive Care Medicine ,medicine.disease_cause ,Autoimmunity ,Mice ,Pulmonary Disease, Chronic Obstructive ,Immune system ,stomatognathic system ,immune system diseases ,Smoke ,B-Cell Activating Factor ,Medicine ,Animals ,Humans ,skin and connective tissue diseases ,B-cell activating factor ,Lung ,Aged ,COPD ,B-Lymphocytes ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Macrophages ,Smoking ,Editorials ,Middle Aged ,Acquired immune system ,medicine.disease ,Immunohistochemistry ,respiratory tract diseases ,Mice, Inbred C57BL ,stomatognathic diseases ,Lymphatic system ,medicine.anatomical_structure ,Immunology ,Female ,medicine.symptom ,business - Abstract
B cell-activating factor (BAFF) plays a major role in activation of B cells and in adaptive humoral immune responses. In chronic obstructive pulmonary disease (COPD), lymphoid follicles have been associated with disease severity, and overexpression of BAFF has been demonstrated within lymphoid follicles of patients with severe COPD.To investigate expression and localization of BAFF in the lungs of patients with COPD and to study the role of BAFF in COPD by antagonizing BAFF in a mouse model of chronic cigarette smoke (CS) exposure.We quantified and localized BAFF expression in lungs of never-smokers, smokers without COPD, and patients with COPD and in lungs of air- or CS-exposed mice by reverse-transcriptase polymerase chain reaction, ELISA, immunohistochemistry, and confocal imaging. Next, to investigate the role of BAFF in COPD, we antagonized BAFF by prophylactic or therapeutic administration of a soluble fusion protein of the BAFF-receptor, BAFFR-Fc, in mice exposed to air or CS for 24 weeks and evaluated several hallmarks of COPD and polarization of lung macrophages.BAFF expression was significantly increased in lungs of patients with COPD and CS-exposed mice. BAFF staining in lymphoid follicles was observed around B cells, CD4(+) cells, dendritic cells, follicular dendritic cells, and fibroblastic reticular cells. Prophylactic and therapeutic administration of BAFFR-Fc in mice reduced pulmonary B-cell numbers and prevented CS-induced formation of lymphoid follicles and increases in immunoglobulin levels. Interestingly, prophylactic BAFFR-Fc administration significantly attenuated pulmonary inflammation and destruction of alveolar walls. Moreover, antagonizing BAFF altered the phenotype of alveolar and interstitial macrophages.BAFF is significantly increased in lungs of patients with COPD and is present around both immune and stromal cells within lymphoid follicles. Antagonizing BAFF in CS-exposed mice attenuates pulmonary inflammation and alveolar destruction.
- Published
- 2015
8. Development of Physical Resources on a Mainstream Site
- Author
-
Liz Flavell
- Subjects
Political science ,Mainstream ,Engineering ethics - Published
- 2014
- Full Text
- View/download PDF
9. Preparing to Include Special Children in Mainstream Schools
- Author
-
Liz Flavell
- Published
- 2014
- Full Text
- View/download PDF
10. Planning and Organisation in Mainstream Settings
- Author
-
Liz Flavell
- Subjects
business.industry ,Mainstream ,Sociology ,Public relations ,business - Published
- 2014
- Full Text
- View/download PDF
11. Access to ICT
- Author
-
Liz Singleton, Iain Ross, and Liz Flavell
- Published
- 2013
- Full Text
- View/download PDF
12. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains
- Author
-
Giles Hassall, David J. Hargreaves, Liz Flavell, Stefan Gerhardt, Claire A. Minshull, Paul Hawtin, Richard A. Pauptit, Attilla Ting, Eileen McCall, Andrew E. Parker, and W. Mark Abbott
- Subjects
Models, Molecular ,ADAM10 ,Disintegrins ,Matrix metalloproteinase ,Crystallography, X-Ray ,Protein Structure, Secondary ,Protein structure ,Structural Biology ,ADAMTS1 Protein ,Catalytic Domain ,Disintegrin ,Humans ,Binding site ,Molecular Biology ,Metalloproteinase ,Binding Sites ,biology ,Chemistry ,ADAMTS ,Active site ,Metalloendopeptidases ,Protein Structure, Tertiary ,ADAM Proteins ,Biochemistry ,biology.protein ,Calcium ,Protein Binding - Abstract
The ADAMTS (a disintegrin-like and metalloproteinase domain with thrombospondin type I motifs) family of proteases plays a role in pathological conditions including arthritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlos type VIIC and Weill-Marchesani genetic syndromes. Here, we report the first crystal structures for a member of the ADAMTS family, ADAMTS-1. Originally cloned as an inflammation-associated gene, ADAMTS-1 has been shown to be involved in tissue remodelling, wound healing and angiogenesis. The crystal structures contain catalytic and disintegrin-like domains, both in the inhibitor-free form and in complex with the inhibitor marimastat. The overall fold of the catalytic domain is similar to related zinc metalloproteinases such as matrix metalloproteinases and ADAMs (a disintegrin and metalloproteinases). The active site contains the expected organisation of residues to coordinate zinc but has a much larger S1' selectivity pocket than ADAM33. The structure also unexpectedly reveals a double calcium-binding site. Also surprisingly, the previously named disintegrin-like domain showed no structural homology to the disintegrin domains of other metalloproteinases such as ADAM10 but is instead very similar in structure to the cysteine-rich domains of other metalloproteinases. Thus, this study suggests that the D (for disintegrin-like) in the nomenclature of ADAMTS enzymes is likely to be a misnomer. The ADAMTS-1 cysteine-rich domain stacks against the active site, suggesting a possible regulatory role.
- Published
- 2007
13. Access to ICT : Curriculum Planning and Practical Activities for Pupils with Learning Difficulties
- Author
-
Liz Singleton, Iain Ross, Liz Flavell, Liz Singleton, Iain Ross, and Liz Flavell
- Subjects
- LC4706.G7
- Abstract
First Published in 2005. Written in plain English and full of ways to broaden pupils'learning experiences this book looks at: the effective use of resources through good planning; helping pupils meet individual targets that fit in with the P levels; the work of City Learning Centres and how to use that expertise to meet specific needs. Written for SENCOs and teachers in mainstream schools, special schools and teaching assistants.
- Published
- 2004
14. Preparing to Include Special Children in Mainstream Schools : A Practical Guide
- Author
-
Liz Flavell and Liz Flavell
- Subjects
- LC4036.G7
- Abstract
Teachers in both special and mainstream schools have to be confident in their abilities to implement inclusion effectively, in order for the child to have any chance of a successful inclusive school career. This book demonstrates how mainstream and special schools can work together in preparing the special school child to succeed in a mainstream environment. It also shows how to prepare existing mainstream pupils and other members of staff involved in or affected by the inclusion process.The author provides photocopiable forms for evaluating pupils'academic and social process and advice on how physical resources, such as sensory rooms, can enhance the learning opportunities of all pupils. She offers jargon-free communication strategies for effective interaction with the child, which is also considered within the framework of the whole-school policy. The book also presents sample lesson plans, resource ideas and plans for daily record keeping for use across the curriculum subjects; and suggestions for ways in which special and mainstream schools can work together to enhance the whole curriculum. Any teacher in a mainstream or special school who is concerned about making inclusion really work for their pupils will find this book an invaluable companion.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.